TD Cowen Begins Coverage on Centessa Pharmaceuticals (NASDAQ:CNTA)

TD Cowen started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note released on Tuesday morning, MarketBeat reports. The firm issued a buy rating on the stock.

A number of other equities analysts have also recently issued reports on CNTA. Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Finally, Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Stock Down 7.0 %

CNTA opened at $16.10 on Tuesday. Centessa Pharmaceuticals has a 12 month low of $6.65 and a 12 month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $16.98 and its 200-day moving average price is $14.33. The company has a market cap of $2.12 billion, a P/E ratio of -10.52 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, equities analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total transaction of $39,709.44. Following the completion of the transaction, the chief executive officer now directly owns 630,661 shares of the company’s stock, valued at $9,661,726.52. This trade represents a 0.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the sale, the insider now directly owns 183,266 shares in the company, valued at $3,236,477.56. The trade was a 5.17 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 368,023 shares of company stock valued at $6,335,574. Corporate insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC grew its position in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. Atria Investments Inc increased its stake in Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares in the last quarter. Quarry LP raised its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 99.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after buying an additional 6,785 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.